Nanoparticle-Fusion Protein Complexes Protect against Mycobacterium tuberculosis Infection

• Published in: Molecular therapy 2018-03, Vol.26 (3), p.822-833
• Main Authors: Hart, Peter, Copland, Alastair, Diogo, Gil Reynolds, Harris, Shane, Spallek, Ralf, Oehlmann, Wulf, Singh, Mahavir, Basile, Juan, Rottenberg, Martin, Paul, Matthew John, Reljic, Rajko
• Format: Article
• Language: English
• Subjects: Acyltransferases - genetics; Acyltransferases - immunology; adjuvant; Adjuvants, Immunologic; Adsorption; Animals; Antigen-presenting cells; Antigens; Antigens, Bacterial - genetics; Antigens, Bacterial - immunology; Bacillus Calmette-Guerin vaccine; Bacterial Proteins - genetics; Bacterial Proteins - immunology; BCG; BCG Vaccine - immunology; CD4 antigen; CD8 antigen; Cell proliferation; Cell-mediated immunity; Cytokines; Cytokines - metabolism; Fusion protein; immunity; Immunity, Cellular; Immunity, Mucosal; Immunization; Immunoglobulin A; Immunoglobulin G; Immunologic Memory; Immunological memory; Infections; Infectious diseases; Inflammation; Interferon regulatory factor 3; Licenses; Lymphocytes T; Medicin och hälsovetenskap; Memory cells; Mice; Mucosa; Mycobacterium tuberculosis; Mycobacterium tuberculosis - immunology; Nanoparticles; Oncology; Original; Proteins; Recombinant Fusion Proteins - immunology; Software; Tuberculosis; Tuberculosis - immunology; Tuberculosis - prevention & control; Tuberculosis Vaccines - immunology; Vaccine efficacy; Vaccines
• ISSN: 1525-0016; 1525-0024; 1525-0024
• DOI: 10.1016/j.ymthe.2017.12.016

Tuberculosis (TB) is the leading cause of death from infectious disease, and the current vaccine, Bacillus Calmette-Guerin (BCG), is inadequate. Nanoparticles (NPs) are an emerging vaccine technology, with recent successes in oncology and infectious diseases. NPs have been exploited as antigen delivery systems and also for their adjuvantic properties. However, the mechanisms underlying their immunological activity remain obscure. Here, we developed a novel mucosal TB vaccine (Nano-FP1) based upon yellow carnauba wax NPs (YC-NPs), coated with a fusion protein consisting of three Mycobacterium tuberculosis (Mtb) antigens: Acr, Ag85B, and HBHA. Mucosal immunization of BCG-primed mice with Nano-FP1 significantly enhanced protection in animals challenged with low-dose, aerosolized Mtb. Bacterial control by Nano-FP1 was associated with dramatically enhanced cellular immunity compared to BCG, including superior CD4+ and CD8+ T cell proliferation, tissue-resident memory T cell (Trm) seeding in the lungs, and cytokine polyfunctionality. Alongside these effects, we also observed potent humoral responses, such as the generation of Ag85B-specific serum IgG and respiratory IgA. Finally, we found that YC-NPs were able to activate antigen-presenting cells via an unconventional IRF-3-associated activation signature, without the production of potentially harmful inflammatory mediators, providing a mechanistic framework for vaccine efficacy and future development. In this issue of Molecular Therapy, Hart and colleagues describe a new vaccine candidate for tuberculosis based on multi-antigen fusion protein-coated nanoparticles. The work showed that mucosal boosting of systemic BCG induced superior immunity and conferred greater protection in Mycobacterium tuberculosis-infected mice than BCG alone. This new vaccine candidate, therefore, merits further development as a potential BCG-boost vaccine against tuberculosis.